After grabbing 10.0 million shares, the institutional investor is now in possession of 10.0 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 35.74% having worth around $2.05 million. Moreover, Armistice Capital LLC increased its share by 1.56 million to have a control over 1.56 million shares. And Heights Capital Management, Inc. raised its holdings to 1.29 million shares by acquiring 1.29 million shares or 4.61% of the stake.
Benitec Biopharma Inc. (BNTC) concluded trading on 01/12/23 at a closing price of $0.20, with 0.32 million shares of worth about $63358.200000000004 changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -79.88% during that period and on Thursday the price saw a loss of about -2.34%. Currently the company’s common shares owned by public are about 27.98M shares, out of which, 25.76M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Franklin Biotechnology Discovery, FTIF SICAV – Biotechnology Discov, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Benitec Biopharma Inc. Franklin Biotechnology Discovery is currently holding 6.2 million shares of worth totaling $1.27 million. The company recently came buying 0.0 shares which brought its stake up to 22.17% of the company’s outstanding shares. Vanguard Extended Market Index Fu, after buying 74773.0 shares, have now control over 0.27% of the stake in the company. It holds 0.0 shares of worth $15328.0.
However, the stock later moved at a day high price of 0.2100, or with a loss of -2.34%. Stock saw a price change of 5.55% in past 5 days and over the past one month there was a price change of 2.12%. Year-to-date (YTD), BNTC shares are showing a performance of 18.34% which decreased to -92.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $3.05 during that period. The average intraday trading volume for Benitec Biopharma Inc. shares is 596.92K. The stock is currently trading 18.20% above its 20-day simple moving average (SMA20), while that difference is up 14.46% for SMA50 and it goes to -74.09% lower than SMA200.
Franklin Advisers, Inc. acquired 10.0 million shares of Benitec Biopharma Inc. having value of about $2.05 million. Benitec Biopharma Inc. (NASDAQ: BNTC) currently have 27.98M outstanding shares and institutions hold larger chunk of about 58.40% of that. Holding of mutual funds in the company is about 20.71% while other institutional holders and individual stake holders have control over 36.18% and 0.39% of the stake respectively.
The stock has a current market capitalization of $5.70M and its 3Y-monthly beta is at 1.14. It has posted earnings per share of -$2.08 in the same period. It has Quick Ratio of 5.70 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BNTC, volatility over the week remained 8.04% while standing at 12.57% over the month.
Analysts are in expectations that Benitec Biopharma Inc. (BNTC) stock would likely to be making an EPS of -$0.18 in the current quarter, while forecast for next quarter EPS is -$0.14 and it is -$0.54 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.25 which is -$0.12 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 31.10% while it is estimated to increase by 30.00% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Benitec Biopharma Inc. (BNTC)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Coverage by Ladenburg Thalmann stated Benitec Biopharma Inc. (BNTC) stock as a Buy in their note to investors on April 20, 2020, suggesting a price target of $14 for the stock. On February 26, 2016, Maxim Group Downgrade their recommendations, while on December 31, 2015, Maxim Group Reiterated their ratings for the stock with a price target of $14. Stock get a Buy rating from Maxim Group on September 16, 2015.